Field-deployable platform for prognostic hepatic cancer screening in low-resource settings

可现场部署的平台，用于在资源匮乏的环境中进行预后性肝癌筛查

• 批准号: 9221887
• 负责人: Marc D Porter
• 金额: $ 39.99万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-02 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9221887
• 关键词: AFP gene; Address; Antibodies; Asia; Asians; Biological Assay; Biological Markers; Biological Sciences; Blood; Businesses; Cancer Center; Cancer Diagnostics; Capital; Cities; Climate; Clinical Research; Communities; Country; Data; Detection; Development; Devices; Diabetes Mellitus; Diagnosis; Diagnostic; Disease; Early Diagnosis; Evaluation; Excision; Generations; Geographic Locations; Geography; Goals; Gold; Health Personnel; Health Planning; Healthcare; Heart Diseases; Hepatitis B; Hepatitis B Prevalence; Hepatitis C; Hospitals; Human; Immunosorbents; Incidence; Income; Institutes; Label; Lectin; Linguistics; Link; Malignant Neoplasms; Malignant neoplasm of liver; Measures; Medical; Minor; Mongolia; Operative Surgical Procedures; Patients; Phase; Physicians; Population; Preparation; Preventive care; Preventive screening; Primary carcinoma of the liver cells; Public Health; Reader; Resources; Risk; Risk Factors; Risk Marker; Sampling; Scientist; Screening for cancer; Serum; Serum Markers; Signal Transduction; Surface; Surgeon; Surgical Oncologist; Technology; Telemedicine; Testing; Time; Training; Treatment outcome; Universities; Utah; Validation; Visit; Visual; Work; acarboxy prothrombin; base; cancer therapy; clinically significant; combat; commercialization; cost; curative treatments; experience; field study; follow-up; health care availability; improved; medically underserved; member; mortality; nano; nanoparticle; outreach program; point of care; portability; prognostic; programs; prototype; screening; socioeconomics; success; tumor; validation studies

PROJECT SUMMARY/ABSTRACT Preventative or curable major diseases such as cancer, heart disease, and diabetes can be successfully treated if detected early in their development via routine physician visits and preventative screening. However, many populations of the world are medically underserved due to resource limitations, geographical location and socio-economic barriers. The overall goal of this project is to develop a portable, inexpensive and easy-to- use point-of-care (POC) platform that can be deployed to prescreen such communities for many of the common, clinically significant diseases in these underserved communities. For development of our initial proof of concept, our integrative team will closely collaborate with partnering physicians in Mongolia on a platform for early diagnosis of hepatocellular carcinoma (HCC) and Hepatitis B and C, which are closely linked to HCC, both of which have a high incidence in this country and in the surrounding region. We propose the development of a portable, easy-to-use, low-cost immunosorbent assay for blood-borne biomarkers of these diseases using a quantitative vertical flow assay (q-VFA) with Raman readout. This platform, which is based on an extensive body of work at the University of Utah, provides a short sample-to- result turn-around-time and can be administered, for example, by a local health care worker or community leader. If positive, referral for further diagnostic evaluation is needed, and the patient can be directed to their nearest medical facility.

项目总结/摘要 预防性或可治愈的重大疾病，如癌症、心脏病和糖尿病， 如果在发育早期通过常规医生就诊和预防性筛查发现，则进行治疗。然而，在这方面， 世界上许多人口由于资源限制、地理位置 社会经济障碍。该项目的总体目标是开发一种便携、廉价和易于操作的 使用即时护理（POC）平台，可以部署用于预先筛选这些社区的许多 在这些缺乏医疗服务的社区中常见的临床上重要的疾病。为了发展我们的初步证据 我们的综合团队将与蒙古的合作医生在一个平台上密切合作， 肝细胞癌（HCC）和与HCC密切相关的B和C型肝炎的早期诊断， 这两种疾病在这个国家和周边地区的发病率都很高。 我们建议开发一种便携式，易于使用，低成本的免疫吸附试验，用于血源性 使用具有拉曼读数的定量垂直流测定（q-VFA）来检测这些疾病的生物标志物。这 该平台基于犹他州大学的大量工作，提供了一个简短的样本， 结果周转时间，并且可以例如由当地卫生保健工作者或社区管理 领袖如果阳性，需要转诊进行进一步的诊断评估，患者可以被引导到他们的 最近的医疗设施